{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:25:57Z","timestamp":1790774757099,"version":"4.1.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T00:00:00Z","timestamp":1782604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T00:00:00Z","timestamp":1782604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"DOI":"10.1007\/s10741-026-10652-0","type":"journal-article","created":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T02:50:07Z","timestamp":1782615007000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Beyond vasodilation: sotatercept and the remodeling hypothesis in hfpef-associated pulmonary hypertension"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8210-6401","authenticated-orcid":false,"given":"Brett W.","family":"Sperry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Carlino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Palazzuoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,28]]},"reference":[{"key":"10652_CR1","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1056\/NEJMoa2213558","volume":"388","author":"MM Hoeper","year":"2023","unstructured":"Hoeper MM, Badesch DB, Ghofrani HA et al (2023) Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N Engl J Med 388:1478\u20131490. https:\/\/doi.org\/10.1056\/NEJMoa2213558","journal-title":"N Engl J Med"},{"key":"10652_CR2","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1056\/NEJMoa2415160","volume":"392","author":"M Humbert","year":"2025","unstructured":"Humbert M, McLaughlin VV, Badesch DB et al (2025) Sotatercept in patients with pulmonary arterial hypertension at high risk for death. N Engl J Med 392:1987\u20132000. https:\/\/doi.org\/10.1056\/NEJMoa2415160","journal-title":"N Engl J Med"},{"key":"10652_CR3","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/NEJMoa2508170","volume":"393","author":"VV McLaughlin","year":"2025","unstructured":"McLaughlin VV, Hoeper MM, Badesch DB et al (2025) Sotatercept for pulmonary arterial hypertension within the first year after diagnosis. N Engl J Med 393:1599\u20131611. https:\/\/doi.org\/10.1056\/NEJMoa2508170","journal-title":"N Engl J Med"},{"key":"10652_CR4","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.126.079918","author":"M Gomberg-Maitland","year":"2026","unstructured":"Gomberg-Maitland M, Tedford RJ, Langleben D et al (2026) Sotatercept for combined post- and pre-capillary pulmonary hypertension associated with heart failure: results from the phase 2, randomized, placebo-controlled CADENCE study. Circulation. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.126.079918","journal-title":"Circulation"},{"issue":"12","key":"10652_CR5","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1001\/jama.2013.2024","volume":"309","author":"MM Redfield","year":"2013","unstructured":"Redfield MM, Chen HH, Borlaug BA et al (2013) Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 309:1268. https:\/\/doi.org\/10.1001\/jama.2013.2024","journal-title":"JAMA"},{"issue":"2","key":"10652_CR6","doi-asserted-by":"publisher","first-page":"1701886","DOI":"10.1183\/13993003.01886-2017","volume":"51","author":"J-L Vachi\u00e9ry","year":"2018","unstructured":"Vachi\u00e9ry J-L, Delcroix M, Al-Hiti H et al (2018) Macitentan in pulmonary hypertension due to left ventricular dysfunction. Eur Respir J 51:1701886. https:\/\/doi.org\/10.1183\/13993003.01886-2017","journal-title":"Eur Respir J"},{"key":"10652_CR7","doi-asserted-by":"publisher","DOI":"10.1161\/circheartfailure.123.011381","author":"SJ Shah","year":"2025","unstructured":"Shah SJ, Bonderman D, Borlaug BA et al (2025) Macitentan for heart failure with preserved or mildly reduced ejection fraction and pulmonary vascular disease: results of the SERENADE randomized clinical trial and open-label extension study. Circ Heart Fail. https:\/\/doi.org\/10.1161\/circheartfailure.123.011381","journal-title":"Circ Heart Fail"},{"key":"10652_CR8","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1378\/chest.14-0106","volume":"146","author":"D Bonderman","year":"2014","unstructured":"Bonderman D, Pretsch I, Steringer-Mascherbauer R et al (2014) Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study. Chest 146:1274\u20131285. https:\/\/doi.org\/10.1378\/chest.14-0106","journal-title":"Chest"},{"key":"10652_CR9","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G et al (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385:1451\u20131461. https:\/\/doi.org\/10.1056\/NEJMoa2107038","journal-title":"N Engl J Med"},{"key":"10652_CR10","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B et al (2022) Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 387:1089\u20131098. https:\/\/doi.org\/10.1056\/NEJMoa2206286","journal-title":"N Engl J Med"},{"key":"10652_CR11","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA et al (2023) Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med 389:1069\u20131084. https:\/\/doi.org\/10.1056\/NEJMoa2306963","journal-title":"N Engl J Med"},{"key":"10652_CR12","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","volume":"391","author":"SD Solomon","year":"2024","unstructured":"Solomon SD, McMurray JJV, Vaduganathan M et al (2024) Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 391:1475\u20131485. https:\/\/doi.org\/10.1056\/NEJMoa2407107","journal-title":"N Engl J Med"},{"key":"10652_CR13","doi-asserted-by":"publisher","unstructured":"Reddy YNV, Frantz RP, Miranda WR et al (2026) Sotatercept in pulmonary arterial hypertension: central, hematologic, and peripheral mechanisms of benefit. J Am Coll Cardiol. https:\/\/doi.org\/10.1016\/j.jacc.2026.02.5103","DOI":"10.1016\/j.jacc.2026.02.5103"},{"key":"10652_CR14","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00818-2026","author":"YNV Reddy","year":"2026","unstructured":"Reddy YNV, Frantz RP, Miranda WR et al (2026) Sotatercept blunts ventilatory drive to carbon dioxide with improved exertional dyspnea in pulmonary arterial hypertension. Eur Respir J. https:\/\/doi.org\/10.1183\/13993003.00818-2026","journal-title":"Eur Respir J"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-026-10652-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-026-10652-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-026-10652-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T15:02:55Z","timestamp":1782658975000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-026-10652-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,28]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10652"],"URL":"https:\/\/doi.org\/10.1007\/s10741-026-10652-0","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,28]]},"assertion":[{"value":"29 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"76"}}